UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
Under the Securities Exchange Act of 1934
For the Month of July 2026
001-36203
(Commission File Number)
CAN-FITE BIOPHARMA LTD.
(Exact name of Registrant as specified in its charter)
26 Ben Gurion Street
Ramat Gan 5257346 Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒
Form 40-F ☐
The first paragraph of the press release attached
hereto as Exhibit 99.1 is hereby incorporated by reference into the registrant’s Registration Statements on Form S-8 (File No. 333-227753, 333-271384 and 333-278525)
and Form F-3 (File Nos. 333-236064, 333-276000, 333-274316, 333-281872, 333-262055,
and 333-294760), to be
a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed
or furnished.
On July 14, 2026, Can-Fite BioPharma Ltd. issued
a press release entitled “Can-Fite Secures Australian Patent Allowance Supporting Namodenoson Development and Marketing in Liver
and Pancreatic Cancer”. A copy of this press release is furnished herewith as Exhibit 99.1.
Exhibit
Index
| Exhibit No. |
|
Description |
| 99.1 |
|
Press Release dated July 14, 2026 |
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
| Date: July 14, 2026 |
By: |
/s/ Motti Farbstein |
| |
|
Motti Farbstein |
| |
|
Chief Executive Officer and Chief Financial Officer |
Exhibit 99.1
Can-Fite Secures Australian Patent Allowance
Supporting Namodenoson Development and Marketing in Liver and Pancreatic Cancer
Ramat Gan, Israel, July 14, 2026 (GLOBE NEWSWIRE) -- Can-Fite
BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small
molecule drugs targeting oncological and inflammatory diseases, today announced that the Australian Patent Office has allowed Patent Application
No. 2021290439 entitled “Treatment of Advanced Metastatic Cancer.”
The patent complements Can-Fite’s rapidly
advancing oncology pipeline. Namodenoson is currently being evaluated in a pivotal Phase 3 study for advanced hepatocellular carcinoma
following FDA and EMA protocol agreement. In pancreatic cancer, the Company recently completed a Phase 2a clinical study demonstrating
an excellent safety profile together with encouraging survival outcomes and durable disease stabilization and is planning a Phase 2b study
evaluating Namodenoson in combination with gemcitabine.
“This patent allowance further strengthens our global intellectual
property portfolio surrounding Namodenoson and reinforces the long-term value of our oncology franchise,” said Pnina Fishman, Ph.D.,
Chairperson and Chief Scientific Officer of Can-Fite BioPharma. “Importantly, the patent supports two of our most advanced oncology
programs—hepatocellular carcinoma and pancreatic cancer—and extends protection for our innovative therapeutic approach in
a major international market.”
Namodenoson selectively targets the A3 adenosine
receptor (A3AR), which is highly expressed in inflammatory and cancer cells. Activation of A3AR has been shown to induce apoptosis of
tumor cells while sparing normal tissues, contributing to the compound’s favorable safety profile demonstrated across clinical studies.
About Namodenoson
Namodenoson is a small orally bioavailable drug
that binds with high affinity and selectivity to the A3 adenosine receptor (A3AR). Namodenoson is currently being evaluated in a pivotal
Phase 3 trial for advanced liver cancer, concluded successfully a Phase 2a study in pancreatic cancer and enroll patients for a Phase
2b trial for the treatment of Metabolic Dysfunction-associated Steatohepatitis (MASH). A3AR is highly expressed in diseased cells whereas
low expression is found in normal cells. This differential expression may be one of the important factors that accounts for the excellent
safety of the drug.
About Can-Fite BioPharma Ltd.
Can-Fite BioPharma Ltd. (NYSE American: CANF)
(TASE: CANF) is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion
dollar markets in the treatment of cancer, liver, and inflammatory disease. The Company’s lead drug candidate, Piclidenoson recently
reported topline results in a Phase 3 trial for psoriasis and commenced a pivotal Phase 3 trial. Can-Fite’s liver drug, Namodenoson,
is being evaluated in a Phase III trial for hepatocellular carcinoma (HCC), a Phase 2b trial for the treatment of MASH, and in a Phase
2a study in pancreatic cancer. Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation
as a second line treatment for HCC by the U.S. Food and Drug Administration. Namodenoson has also shown proof of concept to potentially
treat other cancers including colon, prostate, and melanoma. CF602, the Company’s third drug candidate, has shown efficacy in the
treatment of erectile dysfunction. These drugs have an excellent safety profile with experience in over 1,600 patients in clinical studies
to date. For more information please visit: www.canfite.com.
Forward-Looking Statements
This press release may contain forward-looking
statements, about Can-Fite’s expectations, beliefs or intentions regarding, among other things, the Company’s plans to conduct
a Phase 2b study evaluating Namodenoson in combination with gemcitabine. All statements in this communication, other than those relating
to historical facts, are “forward looking statements”. Forward-looking statements can be identified by the use of forward-looking
words such as “believe,” “expect,” “intend,” “plan,” “may,” “should”
or “anticipate” or their negatives or other variations of these words or other comparable words or by the fact that these
statements do not relate strictly to historical or current matters. Forward-looking statements relate to anticipated or expected events,
activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred,
these statements are inherently subject to known and unknown risks, uncertainties and other factors that may cause Can-Fite’s actual
results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied
by the forward-looking statements. Important factors that could cause actual results, performance or achievements to differ materially
from those anticipated in these forward-looking statements include, among other things, our market and other conditions, history of losses
and needs for additional capital to fund our operations and our inability to obtain additional capital on acceptable terms, or at all;
uncertainties of cash flows and inability to meet working capital needs; the initiation, timing, progress and results of our preclinical
studies, clinical trials and other product candidate development efforts; our ability to advance our product candidates into clinical
trials or to successfully complete our preclinical studies or clinical trials; our receipt of regulatory approvals for our product candidates,
and the timing of other regulatory filings and approvals; the clinical development, commercialization and market acceptance of our product
candidates; our ability to establish and maintain strategic partnerships and other corporate collaborations; the implementation of our
business model and strategic plans for our business and product candidates; the scope of protection we are able to establish and maintain
for intellectual property rights covering our product candidates and our ability to operate our business without infringing the intellectual
property rights of others; competitive companies, technologies and our industry; risks related to not satisfying the continued listing
requirements of NYSE American; and statements as to the impact of the political and security situation in Israel on our business. More
information on these risks, uncertainties and other factors is included from time to time in the “Risk Factors” section of
Can-Fite’s Annual Report on Form 20-F filed with the SEC on March 26, 2026 and other public reports filed with the SEC and in its
periodic filings with the TASE. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof. Can-Fite undertakes no obligation to publicly update or review any forward-looking
statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities
laws.
Contact
Can-Fite BioPharma
Motti Farbstein
info@canfite.com
+972-3-9241114
